Overview

• VYNE Q3 net loss decreases compared to last year

• Company progressing with strategic review to maximize shareholder value

Outlook

• VYNE is conducting a strategic review to explore options like partnerships or mergers

• Company expects cash runway to last into the first half of 2027

• VYNE is conducting a 12-week toxicology study for VYN202 to lift a clinical hold

Result Drivers

• STRATEGIC REVIEW - Co is evaluating strategic alternatives to maximize shareholder value, including potential partnerships and transactions

• COST REDUCTIONS - Co implemented cost reductions to extend cash runway into first half of 2027

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Vyne Therapeutics Inc is $3.25, about 89.6% above its November 5 closing price of $0.34

Press Release: ID:nGNXbBrRvS

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)